Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$18.5B
1,149M shares
52-week range
$9.43 – $18.39
76% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
www.viatris.comNo one on the platform currently holds VTRS.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 725,884 | $9.8M |
| Renaissance Technologiesas of 2024-09-30 | 301,316 | $3.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-21 | $0.1200 | 2026-09-16 |
| 2026-05-22 | $0.1200 | 2026-06-17 |
| 2026-03-09 | $0.1200 | 2026-03-18 |
| 2025-11-24 | $0.1200 | 2025-12-15 |
| 2025-08-22 | $0.1200 | 2025-09-15 |
| 2025-05-23 | $0.1200 | 2025-06-16 |
| 2025-03-10 | $0.1200 | 2025-03-18 |
| 2024-11-22 | $0.1200 | 2024-12-13 |
| 2024-08-23 | $0.1200 | 2024-09-13 |
| 2024-05-23 | $0.1200 | 2024-06-14 |
No one on the platform has traded VTRS yet.
| 2024-03-08 | $0.1200 | 2024-03-18 |
| 2023-11-22 | $0.1200 | 2023-12-15 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $14.8B | +4.7% | $2.45 | $2.42–$2.49 | 6.6× | 5 |
| 2027 | $15.1B | +1.8% | $2.63 | $2.56–$2.71 | 6.2× | 5 |
| 2028 | $15.4B | +2.5% | $2.85 | $1.76–$3.94 | 5.7× | 2 |
| 2029 | $15.0B | -3.0% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $0.60 | $0.69 | +14.8% |
| 2026-05-07 | $0.50 | $0.59 | +17.5% |
| 2026-02-26 | $0.53 | $0.57 | +7.1% |
| 2025-11-06 | $0.62 | $0.67 | +7.9% |
| 2025-08-07 | $0.56 | $0.62 | +11.5% |
| 2025-05-08 | $0.49 | $0.50 | +1.6% |
| 2025-02-27 | $0.61 | $0.54 | -11.5% |
| 2024-11-07 | $0.68 |
| $0.75 |
| +10.8% |
| $20.0B |
| — |
| IONSIonis Pharmaceuticals, Inc. | $57.24 | +2.45% | $9.5B | — |
| MRNAModerna, Inc. | $63.32 | -0.52% | $25.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
$LXRX $NVO $VTRS Dr Edelman is total proponent of Zynquista for T1 - A towering authority in his field, that completely has our back = $LXRX
View on StockTwits ↗$LXRX watch: Lexicon is exhibiting at TCOYD [Taking Control Of Your Diabetes] ONE 2026, Aug 14-16, San Diego. TCOYD is led by Dr. Steve Edelman (Founder/Director, UCSD Prof. of Medicine) and Dr. Jeremy Pettus (UCSD Assoc. Prof.) — independent physicians, not Lexicon staff, but longtime T1D [type 1 diabetes] advocates for options beyond insulin. Fresh catalyst: on Lexicon's Q2 2026 call, mgmt said STENO1 (Steno Diabetes Center, Denmark) is nearing the exposure threshold FDA flagged as sufficient for NDA [New Drug Application] resubmission of Zynquista (sotagliflozin) in T1D. Exposure expected by end of Aug 2026; DKA [diabetic ketoacidosis] rates similar to standard-of-care, below earlier trials. Resubmission targeted Q4 2026. Watching conference + STENO1 data into Q4. NFA. DYOR. https://www.linkedin.com/posts/lexicon-pharmaceuticals_lexicon-t1d-dpnp-activity-7493668586708885504-LpTh?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA $VTRS $NVO
View on StockTwits ↗$LXRX Canada, Australia = Inpefa... and many more to come. $VTRS hustling.
View on StockTwits ↗Stocks hitting new 52-week highs today: $BRK.B $RTX $BAC $GE $VTRS A broad group of sectors are showing strength: Financials Industrials Healthcare Aerospace Energy Consumer When multiple sectors are making new highs, it can signal broader market participation beyond just a handful of mega-cap names. The key is identifying which companies have the fundamentals and growth catalysts to continue the trend. Follow my profile for more market trends, stock ideas, and investment insights. NFA. DYOR.
View on StockTwits ↗Fresh 52-Week Highs Alert! These names all reached new 52-week highs during today’s session: $BRK.B $RTX $BAC $GE $VTRS Strong momentum, improving sentiment, and buyers stepping in across multiple sectors. Which one is still just getting started? Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened
View on StockTwits ↗$VTRS For a company in the peptide and stem cell space RMTG is executing at a level that is rare they have revenue they have growth and they have profits BSEM is still in the development stage financially with huge losses every quarter the difference in maturity between the two companies is striking.
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-6-viatris-inc-stock/ $VTRS Viatris Earnings Transcript
View on StockTwits ↗$LXRX $VTRS = our ONLY access to sales is just getting started with roll out... Street had this too high, to save some shorts and give a few whales nice entries. Before what really matters = TYPE 1 Diabetes resubmission.
View on StockTwits ↗$VTRS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.10 • Reported revenue of $3.76B up 4.88% YoY • Viatris Inc. raised its 2026 financial guidance midpoints, now expecting total revenues of $14,550 million to $14,950 million, adjusted EBITDA of $4,300 million to $4,500 million, and adjusted EPS of $2.45 to $2.59.
View on StockTwits ↗Wall St is expecting 0.60 EPS for $VTRS Q2 [Reporting 08/06 BMO] http://www.estimize.com/intro/vtrs?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$ELTP 10-K for Elite Pharma. "Recent Developments: On April 2, 2026, we announced the comercial launch of our generic methadone hydrochloride 5 mg and 10 mg tablets. 💊 The product is marketed and sold under the Elite Labs label and represents an expansion of the Elite Pharmaceuticals' generic product portfolio. On June 1, 2026, Elite filed an Abbreviated New Drug Application [ANDA] with the US Food and Drug Administration for a generic version of an undisclosed 🤔 drug product in the class of medications caled anticoagulants."[Eloquis] 😲 $TEVA $JNJ 😲 $VTRS
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.